Bovine vascular regulatory polypeptides evaluated for reducing restenosis after femoropopliteal bypass with synthetic grafts

Currently, extensive occlusive lesions of the superficial femoral artery are commonly treated with femoropopliteal bypass grafting above the knee. When autogenous veins are unavailable, synthetic grafts are used, but these are prone to restenosis in the anastomotic zone, primarily due to endothelial dysfunction. This complication significantly contributes to thrombosis and graft failure. Normalizing endothelial function is crucial for improving long-term patency. A complex of bovine vascular regulatory polypeptides is being explored as a potential agent to address this critical gap by restoring endothelial health.

This study enrolled 60 patients with stage III-IV lower extremity arterial atherosclerosis who underwent femoropopliteal bypass grafting above the knee using an 8 mm polytetrafluoroethylene synthetic prosthesis. Patients were divided into two groups of 30 each. Group I received standard therapy plus Slavinorm® (bovine vascular regulatory polypeptides) via intramuscular injections twice a week for 5 weeks, No. 10. Group II received standard therapy alone. Efficacy was assessed by measuring ankle-brachial index (ABI), ultrasound of proximal and distal anastomoses, and pain-free walking distance (PFWD) at baseline, 1, 3, 6, 9, and 12 months post-surgery.

The abstract provided only baseline patient characteristics, stating that in both Group I and Group II, the average ABI value before treatment was 0.46.

The abstract did not provide specific post-treatment or comparative results regarding ABI changes, ultrasound findings related to restenosis, or improvements in PFWD between the Slavinorm® group and the standard therapy group. Therefore, the effectiveness of the bovine vascular regulatory polypeptides in this study cannot be determined from the provided abstract.